How To Use ZOMETA® | Patient Case Study: Multiple Myeloma

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

ZOMETA Patient Case Study: Multiple Myeloma

ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETA� Multiple Myeloma Patient Case Study � Marie

Marie T.

Aged 62 years
Lives and works on a family farm
Enjoys walking her dogs with her husband

Page

1 2 3

In patients like Marie, the vicious cycle of bone destruction is ongoing

Osteoclasts and osteoblasts continually weaken bone in a vicious cycle of destruction^7,8

ZOMETA®: Osteoclasts and osteoblasts continually weaken bone in SREs

Because bone is constantly being attacked, ZOMETA^® must be dosed
every 3 to 4 weeks^7,9

Page

1 2 3

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

In patients like Marie, the vicious cycle of bone destruction is ongoing

Because bone is constantly being attacked, ZOMETA® must be dosedevery 3 to 4 weeks7,9

Because bone is constantly being attacked, ZOMETA^® must be dosed
every 3 to 4 weeks^7,9